Ken Research Stated Saudi Arabia Pharmaceutical Logistics Market to Reach USD 1.22 Billion

Ken Research projects Saudi Arabia’s pharmaceutical logistics market will expand from approximately USD 789.34 million in 2025 to roughly USD 1,218.87 million by 2031, growing at a compound annual growth rate (CAGR) of 7.51%. The 81-page market study highlights import-driven demand, expanding cold-chain requirements, and increasing adoption of integrated third‑party logistics as primary catalysts for market expansion.

"Saudi Arabia's Pharmaceutical Logistics Market is moving beyond conventional transportation and storage toward an integrated healthcare‑supply‑chain ecosystem connecting import clearance, validated warehousing, temperature‑controlled transport, serialization, quality release, national replenishment, and patient‑centric delivery," said Namit Goel, Co‑Founder at Ken Research. "The cold‑chain share of market revenue is projected to increase from 21.1% in 2025 to 26.4% by 2031 as biologics, vaccines, specialty therapies, and time‑critical medicines become more important."

Key market dynamics

The report identifies several measurable trends reshaping logistics needs across Saudi Arabia:

• Import dependence: Pharmaceutical imports totaled approximately USD 8.21 billion in 2024, with import dependence near 70% in 2023. Saudi Arabia accounted for more than 45% of pharmaceutical imports across the GCC, amplifying regional logistics opportunities.
• Cold‑chain growth: Cold‑chain revenue share is forecast to rise from 21.1% in 2025 to 26.4% by 2031, reflecting rising distribution of biologics, vaccines and other temperature‑sensitive therapies.
• Domestic manufacturing: The kingdom had about 42 SFDA‑registered pharmaceutical factories at the report’s baseline. Domestic manufacturing supplied roughly 30% of pharmaceutical demand, with official localization ambitions targeting near 40%.
• Geography and coverage: Saudi Arabia spans approximately 2.24 million square kilometres, creating logistical complexity that favors providers offering broad route coverage, regional capacity and contingency planning beyond primary metropolitan areas.

Operational implications and service models

The analysis stresses the commercial value of integrated logistics models that combine international freight capabilities with national distribution. Integrated providers can manage supplier pickup, air or sea transportation, customs documentation, quality‑controlled transfer, warehouse receipt and temperature‑controlled delivery under single governance—reducing handover risk and simplifying accountability for manufacturers, distributors and healthcare organisations.

Localization of pharmaceutical manufacturing is broadening the logistics profit pool: inbound materials management for factories, quality‑release operations, production replenishment, finished‑goods distribution and potential exports. Multi‑client healthcare distribution centres near manufacturing clusters are identified as an efficiency play, provided strict segregation, access controls and documented temperature control systems are maintained.

Outlook

Ken Research’s study frames the next five years as a period of structural change in Saudi pharmaceutical logistics, driven by rising imports, greater domestic production and the increasing prevalence of temperature‑sensitive therapies. For logistics providers, investment priorities include validated warehousing, cold‑chain capacity, digital traceability and integrated control‑tower services to manage multi‑modal inbound flows, customs clearance and nationwide replenishment. The market intelligence report, which profiles ten companies and evaluates seven segmentation categories across 34 chapters, positions these capabilities as central to capturing the projected growth to USD 1.22 billion by 2031.